Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
In: Frontiers in Endocrinology, Jg. 13 (2022-09-01)
Online
academicJournal
Zugriff:
Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, can stimulate glucose-dependent insulin secretion, particularly by binding to VPAC2 receptors. VIP also promotes islet β-cell proliferation through the forkhead box M1 pathway, but the specific molecular mechanism remains to be studied. The clinical application of VIP is limited because of its short half-life and wide distribution in the human body. Based on the binding properties of VIP and VPAC2 receptors, VPAC2-selective agonists have been developed to serve as novel hypoglycemic drugs. This review summarizes the physiological significance of VIP in glucose homeostasis and the potential therapeutic value of VPAC2-selective agonists in type 2 diabetes.
| Titel: |
Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
|
|---|---|
| Autor/in / Beteiligte Person: | Hou, Xintong ; Yang, Dan ; Yang, Guimei ; Li, Mengnan ; Zhang, Jian ; Zhang, Jiaxin ; Zhang, Yi ; Liu, Yunfeng |
| Link: | |
| Zeitschrift: | Frontiers in Endocrinology, Jg. 13 (2022-09-01) |
| Veröffentlichung: | Frontiers Media S.A., 2022 |
| Medientyp: | academicJournal |
| ISSN: | 1664-2392 (print) |
| DOI: | 10.3389/fendo.2022.984198 |
| Schlagwort: |
|
| Sonstiges: |
|